Evkeeza market set for growth on genetic screening and rare disease demand

The Business Research Company says the Evkeeza market is positioned for steady expansion through 2035 as genetic screening, biologic adoption and reimbursement for rare diseases improve access to treatment. North America is expected to stay the largest market in 2025, while Asia-Pacific is projected to grow the fastest.

Why it matters: - Evkeeza is used for homozygous familial hypercholesterolemia, a rare genetic disorder tied to extremely high cholesterol. - Market growth reflects broader demand for targeted treatments in rare lipid disorders, where standard therapies often fall short. - Expanding access to genetic testing and specialty care could bring more eligible patients into treatment.

What happened: - The Business Research Company published its Evkeeza Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report says the Evkeeza market is attracting more attention as advances in genetic research and treatment options improve outcomes for rare lipid disorders. - The report identifies Evkeeza as a monoclonal antibody therapy that inhibits angiopoietin-like 3, or ANGPTL3, to reduce LDL cholesterol and other lipid fractions. - A free sample of the report is available here. - The full report is available here.

The details: - Historical growth was driven by limited effectiveness of traditional statins, the long-term burden of familial hypercholesterolemia, early adoption of biologic lipid therapies, unmet medical needs among HoFH patients and specialist-driven treatment uptake. - Future growth is expected to be supported by rising genetic screening for lipid disorders, greater use of biologics, expanded reimbursement for rare diseases, advances in lipid metabolism research and more specialty cardiology centers. - Major trends include wider availability of monoclonal antibody therapies, increased focus on rare lipid disorders, expanding precision lipid-lowering treatments, broader use of targeted ANGPTL3 inhibitors and improved outcomes in severe hypercholesterolemia. - The report says rising prevalence of genetic disorders worldwide is a key driver, helped by better diagnostics and greater exposure to environmental risk factors. - The report points to the broader rise in genetic illness demand, citing American Society of Hematology data from June 2024 that says the global population affected by sickle cell disease is expected to grow by nearly 30% by 2050. - The expanding number of drug approvals is also supporting the market by accelerating access to innovative treatments and orphan drug incentives. - The Personalized Medicine Coalition says the FDA approved 16 new personalized therapies for rare diseases in 2023, more than double the six approvals in 2022. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis.

Between the lines: - Evkeeza’s outlook is tied to two shifts happening at once: more patients being identified through genetic screening and more healthcare systems willing to pay for rare-disease therapies. - The report’s emphasis on specialty cardiology centers suggests treatment access will remain concentrated in specialized care settings rather than broad primary care channels. - North America’s lead points to stronger infrastructure and faster uptake of advanced therapies, while Asia-Pacific’s growth signal suggests the next wave of expansion may come from infrastructure buildout and screening programs.

What's next: - North America is projected to remain the largest Evkeeza market in 2025. - Asia-Pacific is projected to be the fastest-growing region through the forecast period. - The company says the broader 2026 report set will continue to add strategic tools and updated graphics for market tracking. - More information is available at The Business Research Company.